K.J.D. Kol


  1. MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type non-small cell lung adenocarcinoma cells

    Stutvoet, T., Kol, A., de Vries, E., de Bruyn, M., Fehrmann, R., van Scheltinga, A. T. & de Jong, S., Nov-2018, p. E78-E79. 2 p.

    Research output: Contribution to conferencePosterAcademic

  2. A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer

    Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., Van Gool, I. C., Eggink, F. A., Wouters, M. C., Komdeur, F. L., van der Slikke, E. C., Creutzberg, C. L., Kol, A., Plat, A., Glaire, M., Church, D. N., Nijman, H. W. & de Bruyn, M., 2019, In : Cancer immunology research. 38 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

    Kol, K. J-D., 2019, [Groningen]: Rijksuniversiteit Groningen. 175 p.

    Research output: ThesisThesis fully internal (DIV)Academic

  4. (89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

    Pool, M., Kol, A., de Jong, S., de Vries, E. G. E., Lub-de Hooge, M. N. & Terwisscha van Scheltinga, A. G. T., 2017, In : mAbs. 9, p. 1370-1378 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells

    Kol, A., Terwisscha van Scheltinga, A., Pool, M., Gerdes, C., de Vries, E. & de Jong, S., 11-Jul-2017, In : Oncotarget. 8, 28, p. 45432-45446 15 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (9) »

View graph of relations

ID: 378071